Lipid components of solid lipid nanoparticles (SLN lipids)

Lipid components of solid lipid nanoparticles (SLNs) are the structural building blocks, typically comprising triglycerides (e.g., tristearin), partial glycerides, fatty acids (e.g., stearic acid), or waxes (e.g., cetyl palmitate), which remain solid at both room and body temperature (Mukherjee et al., 2009, Indian J Pharm Sci). These lipids form a solid matrix that encapsulates lipophilic drugs, protecting them from chemical degradation and providing a mechanism for controlled drug release (Puri et al., 2009, Crit Rev Ther Drug Carrier Syst). SLNs are not therapeutic targets themselves but serve as advanced drug delivery vehicles designed to improve the bioavailability of poorly water-soluble compounds and enable site-specific delivery (Wissing et al., 2004, Adv Drug Deliv Rev). By utilizing physiological lipids, SLNs minimize the risk of acute and chronic toxicity compared to some polymeric nanoparticles (Müller et al., 2000, Eur J Pharm Biopharm). They are widely investigated for applications in oncology, neurology, and infectious diseases to enhance the therapeutic index of various drugs (Uner & Yener, 2007, Int J Nanomedicine).

Other names

Solid lipid nanoparticle matrixLipidic nanocarriersSLN lipidsSolid lipid nanospheres

SLNs function as delivery vehicles that encapsulate drugs within a solid lipid matrix, facilitating controlled release and protecting the payload from enzymatic or chemical degradation (Müller et al., 2000, Eur J Pharm Biopharm). They can enhance drug absorption via the lymphatic system or through the enhanced permeability and retention (EPR) effect in tumor tissues (Wissing et al., 2004, Adv Drug Deliv Rev).